[Fundamental study of imipenem/cilastatin sodium in obstetrics and gynecology].
Following results were obtained from drip intravenous administration of imipenem/cilastatin sodium (MK-0787/MK-0791) (500 mg/500 mg) by measuring concentration of MK-0787 in uterine arterial plasma, cubital venous plasma, oviduct, ovary and several sites in uterine tissue in cases of simple hysterectomy, and pelvic cavity fluid in cases of radical operation. Cervix uteri, portio vaginalis, myometrium showed higher concentration among various uterine tissues in any time after the end of administration. In cases of radical operation, the pelvic cavity fluid showed 6.6 approximately 7.8 micrograms/ml at 5 hours after the end of administration. In the field of obstetrics and gynecology, it was considered that MK-0787/MK-0791 has good efficacy in infections especially caused by Gram-positive aerobic bacteria.
Taguchi
K
K
Saito
Y
Y
Seki
H
H
Murata
M
M
Shidara
Y
Y
Sayama
T
T
Sato
Y
Y
Isobe
K
K
D000328:Adult; D015377:Cilastatin; D003521:Cyclopropanes / Q000008:administration & dosage*; D004150:Dipeptidases / Q000037:antagonists & inhibitors*; D004338:Drug Combinations; D005260:Female; D005836:Genitalia, Female / Q000378:metabolism*; D006801:Humans; D015378:Imipenem; D007262:Infusions, Intravenous; D008875:Middle Aged; D013845:Thienamycins / Q000008:administration & dosage / Q000097:blood / Q000378:metabolism*
D003521:Cyclopropanes; D004338:Drug Combinations; D013845:Thienamycins; D015377:Cilastatin; D015378:Imipenem; D004150:Dipeptidases